Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
IRONWOOD PHARMACEUTICALS INC director-related entities reported major share sales alongside a small equity grant. Investment vehicles advised by Sarissa Capital Management LP sold a total of 6,730,800 shares of Class A Common Stock on March 17, 2026 in open-market transactions at prices between $3.05 and $3.31 per share, leaving 9,188,635 shares held indirectly. Separately, Dr. Alexander J. Denner received a grant of 4,451 shares on March 13, 2026 under the company’s non-employee director compensation policy, bringing his directly held shares to 256,309. Footnotes state Sarissa Capital and its funds directly hold the sold and remaining indirect shares, with each party, including Dr. Denner, disclaiming beneficial ownership beyond their pecuniary interest.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo received an equity grant of 136,612 shares of Class A Common Stock as a stock award. The shares were acquired at no cash cost to him as a grant or award, rather than an open-market purchase.
The award was granted in the form of restricted stock units as an annual performance award and will vest in four equal installments, with 25% of the underlying shares vesting on each approximate anniversary of the grant date. Following this grant, Minardo directly holds a total of 500,498 shares of Class A Common Stock.
Ironwood Pharmaceuticals reported that Chief Financial Officer Gregory S. Martini received an equity compensation grant of 136,612 shares of Class A Common Stock on March 10, 2026. The award is structured as restricted stock units granted as an annual performance award.
The award vests in four equal installments, with 25% of the shares vesting on each approximate anniversary of the grant date. Following this grant, Martini directly holds 297,213 shares of Class A Common Stock. This is a compensation-related acquisition, not an open-market purchase or sale.
Gaskins Tammi L reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Commercial Officer Tammi L. Gaskins received an equity grant of 136,612 shares of Class A Common Stock in the form of restricted stock units. These units were granted at no cash cost and represent a compensation award rather than an open-market purchase.
The award, described as an annual performance grant, vests in four equal installments of 25% on each approximate anniversary of the grant date, tying value to continued service and performance over time. Following this grant, Gaskins’ direct holdings increased to 350,350 shares of Class A Common Stock.
Shetzline Michael reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals reported that SVP and Chief Medical Officer Michael Shetzline received a grant of 136,612 shares of Class A Common Stock as an annual performance-related restricted stock unit award. The grant has no purchase price and will vest in 25% increments on each approximate anniversary of the grant, leaving him with 658,037 shares directly owned after the award.
Silver Ronald reported acquisition or exercise transactions in this Form 4 filing.
Ironwood Pharmaceuticals’ principal accounting officer Ronald Silver received a stock-based compensation grant. He was awarded 163,934 shares of Class A Common Stock as restricted stock units, with no cash paid per share. The award vests in four equal annual installments. Following this grant, he directly holds 416,570 shares.
MCCOURT Thomas A reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Executive Officer Thomas A. McCourt received a grant of 409,836 shares of Class A Common Stock as a restricted stock unit award. This annual performance award vests in three equal installments of 33.33% on each approximate anniversary of the grant.
Following this award, McCourt directly holds 1,898,838 shares of Class A Common Stock. The grant is compensation-related and was recorded at no cash purchase price per share.
Ironwood Pharmaceuticals, Inc. reported that it has met the liquidity conditions tied to the “Maturity Date” definition in its existing Credit Agreement with Wells Fargo Bank, National Association, as administrative agent. As a result, the revolving credit facility’s maturity date remains December 31, 2028, under the current terms of the Credit Agreement.
Ironwood Pharmaceuticals focuses on gastrointestinal and rare diseases, built around LINZESS and its apraglutide pipeline. The company co-commercializes LINZESS for IBS-C and chronic constipation with AbbVie in the U.S. and relies on partners such as AbbVie, Astellas and AstraZeneca globally.
Through its VectivBio acquisition, Ironwood is advancing apraglutide for short bowel syndrome; after positive Phase III data, the FDA required a confirmatory Phase III trial (STARS-2), with site initiations expected in the second quarter of 2026. Ironwood ceased development of IW-3300 after Phase II results.
Revenue concentration is high, with the U.S. contributing 97.7% of 2025 revenue and LINZESS collaborations comprising substantially all revenue. Government pricing pressure is rising: LINZESS was selected for Medicare price negotiation, and its Maximum Fair Price from 2027 will be $136 for a 30-day supply, alongside a LINZESS list price cut effective January 1, 2026.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo reported automatic sales of 36,492 shares of Class A common stock to cover tax withholding on vested restricted stock units. These open-market transactions occurred on February 23 and 24 at weighted average prices of $3.81 and $3.66 per share, within disclosed intraday price ranges.
After these sell-to-cover trades, Minardo directly held 363,886 Ironwood shares. The filing notes that the sales were executed automatically to satisfy tax obligations and did not represent discretionary trading decisions.